CalciMedica shares are trading higher after the company announced positive data from its Phase 2B carpo trial of auxora in acute pancreatitis (ap) with accompanying systemic inflammatory response syndrome.
Portfolio Pulse from Benzinga Newsdesk
CalciMedica shares rose following the announcement of positive Phase 2B trial results for auxora in treating acute pancreatitis with systemic inflammatory response syndrome.
October 30, 2024 | 2:28 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
CalciMedica's stock price increased due to positive results from its Phase 2B trial of auxora, which showed promise in treating acute pancreatitis with systemic inflammatory response syndrome.
The positive trial results are a significant milestone for CalciMedica, potentially leading to further development and commercialization of auxora. This news likely boosts investor confidence, driving the stock price up.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100